Amgen Inc. (BIT:1AMGN)
Italy · Delayed Price · Currency is EUR | Market Cap | 203.41B +55.4% |
| Revenue (ttm) | 33.34B +9.1% |
| Net Income | 7.65B +32.1% |
| EPS | 14.09 +31.6% |
| Shares Out | n/a |
| PE Ratio | 26.58 |
| Forward PE | 18.52 |
| Dividend | 8.50 (2.23%) |
| Ex-Dividend Date | Aug 20, 2026 |
| Volume | 161 |
| Open | 380.00 |
| Previous Close | 380.55 |
| Day's Range | 378.60 - 381.80 |
| 52-Week Range | 230.90 - 382.95 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial numbers in USD Financial StatementsNews
Amgen price target raised to $435 from $400 at Wells Fargo
Wells Fargo raised the firm’s price target on Amgen (AMGN) to $435 from $400 and keeps an Equal Weight rating on the shares. Given where the stock currently trades, the…
Amgen price target raised to $435 from $400 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Amgen (AMGN) to $435 from $400 and keeps an Equal Weight rating on the shares. The firm says its…
AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., Sept. 2, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m.
UK regulator suspends Amgen's Tavneos for new patients over unreliable data
Britain's medicines regulator on Tuesday suspended the use and sale of Amgen's rare-disease drug, Tavneos, to new patients, saying the main study supporting its approval was unreliable.
Trump administration to announce drug pricing deals
U.S. President Donald Trump is expected to announce a new round of drug-pricing agreements on Monday, a White House official said, part of a push to make healthcare more affordable for Americans.
Amgen Repatha reduces risk of death in high-risk adults for first heart attack
Amgen (AMGN) announced new findings showing Repatha reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein…
AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients in a Phase 3 Trial Separate Gl...
Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements
Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis showed that AstraZeneca (AZN) and Amgen’s (AMGN) TEZSPIRE demonstrated statistically significant...
AstraZeneca Stock (AZN) Slides Despite New Esophagus Drug Trial Success
Shares in pharmaceuticals giant AstraZeneca ($AZN) and peer Amgen ($AMGN) both dropped in pre-market trading despite hailing successful trial results for a new esophagus drug. AZN said that its asthma...
Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints
Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 CROSSING trial of Tezspire in patients living with eosinophilic esophagitis. Tezspire demonstrated statistically signific...
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52 Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports ...
White House to announce new drug pricing deals with biotechs, Bloomberg News reports
U.S. President Donald Trump's administration is planning to announce a new round of drug-pricing agreements with midsize biotech companies on Monday, Bloomberg News reported on Wednesday, c...
Amgen price target raised to $457 from $427 at Piper Sandler
Piper Sandler analyst David Amsellem raised the firm’s price target on Amgen (AMGN) to $457 from $427 and keeps an Overweight rating on the shares. The firm says monthly third-party…
Amgen price target raised to $362 from $351 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Amgen (AMGN) to $362 from $351 and keeps an Overweight rating on the shares.
Amgen price target raised to $460 from $375 at Argus
Argus raised the firm’s price target on Amgen (AMGN) to $460 from $375 and keeps a Buy rating on the shares. The company has a strong pipeline of potential new…
Amgen price target raised to $400 from $350 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Amgen (AMGN) to $400 from $350 and keeps a Neutral rating on the shares. The revised estimates better capture Amgen’s near-term commercial…
Amgen price target raised to $352 from $303 at Mizuho
Mizuho raised the firm’s price target on Amgen (AMGN) to $352 from $303 and keeps a Neutral rating on the shares. The firm updated the company’s model post the Q2…
Amgen price target raised to $380 from $360 at Barclays
Barclays analyst Emily Field raised the firm’s price target on Amgen (AMGN) to $380 from $360 and keeps an Equal Weight rating on the shares. The company’s “broad-based” portfolio strength…
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Amgen price target raised to $388 from $343 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Amgen (AMGN) to $388 from $343 and keeps a Neutral rating on the shares after updating the firm’s model following…
Amgen price target raised to $405 from $345 at Citi
Citi raised the firm’s price target on Amgen (AMGN) to $405 from $345 and keeps a Neutral rating on the shares. The firm updated the company’s model post the Q2…
Amgen price target raised to $345 from $335 at Bernstein
Bernstein raised the firm’s price target on Amgen (AMGN) to $345 from $335 and keeps a Market Perform rating on the shares. Amgen reported another strong quarter, with a 6.8%…
Amgen Earnings Call Transcript: Q2 2026
Q2 2026 revenues rose 10% year-over-year to over $10 billion, driven by strong growth across six key product areas, with 22 products posting double-digit sales gains. Guidance for 2026 was raised, reflecting robust execution, expanding pipeline, and continued investment in innovation.
Amgen Earnings release: Q2 2026
Amgen released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Amgen Slides: Q2 2026
Amgen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.